Concepedia

Assessment of the HER2DX Assay in Patients With <i>ERBB2</i>-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab

Adrienne G. Waks, Esther R. Ogayo, Laia Paré, Mercedes Marín‐Aguilera, Fara Brasó‐Maristany, Patricia Galván, Oleguer Castillo, Olga Martínez‐Sáez, Ana Vivancos, Patricia Villagrasa,

JAMA Oncology · 2023 · 34 citations · 7 references

DOIFull text

Open access

Abstract

The results of this diagnostic/prognostic study suggest that the HER2DX pCR score assay could predict pCR following treatment with deescalated neoadjuvant paclitaxel with trastuzumab and pertuzumab in patients with early-stage ERBB2+ BC. The HER2DX pCR score might guide therapeutic decisions by identifying patients who are candidates for deescalated or escalated approaches.

References

7

STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies

Patrick M. Bossuyt, Johannes B. Reitsma, David E. Bruns et al. · BMJ · 2015 · 3.1K citations · Full text

, , +19

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

W. Fraser Symmans, Florentia Peintinger, Christos Hatzis et al. · Journal of Clinical Oncology · 2007 · 1.6K citations · Full text

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology · 2021 · 395 citations · Full text

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

Aleix Prat, Valentina Guarneri, Tomás Pascual et al. · EBioMedicine · 2022 · 133 citations · Full text

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Aleix Prat, Valentina Guarneri, Laia Paré et al. · The Lancet Oncology · 2020 · 72 citations · Full text

, , +10